Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Thursday, August 15, 2019

Cardiac Rehab Might Benefit Stroke Survivors, Too

'Might' is way too milquetoast an answer. Come back when you have a protocol. 'Might' is lazy and I would have you fired for that. 

Cardiac Rehab Might Benefit Stroke Survivors, Too

Mixed aerobics and walking was most beneficial

  • by Staff Writer, MedPage Today
Walking and aerobic capacity improved modestly for stroke survivors participating in group aerobic exercise initiatives comparable to cardiac rehabilitation programs, a meta-analysis found.
Aerobic exercise had a "small" but significant effect size of 0.38 (95% CI 0.27–0.49) for improvement in the composite mean of aerobic capacity outcome measures (6-minute walk test, VO2 peak, maximum walking speed, and self-selected walking speed).
Looking at each activity type, mixed aerobic activity had the largest effect size at 0.61, followed by walking (ES 0.37), but cycling alone had an effect size of just 0.24, reported Elizabeth Regan, PT, DPT, of the University of South Carolina in Columbia, and colleagues in the Journal of the American Heart Association.
"Cardiac rehab could work for stroke survivors, programs like cardiac rehab are beneficial, and they are beneficial regardless of how long it's been since they've had their stroke," concluded Regan in an interview with MedPage Today. "Stroke survivors could definitely benefit from community programs that have an aerobic fitness focus, and cardiac rehab could potentially fill the gap."
Offering cardiac rehabilitation to stroke survivors is an effective way of improving health status without coming up with new programs, the researchers emphasized, calling the findings clinically important for those with mild post-stroke impairment.
"Cardiac rehabilitation programs are an excellent setting to provide individualized exercise prescription and to teach patients how to exercise safely on their own," agreed Vera Bittner, MD, MSPH, of the University of Alabama in Birmingham, who was not involved in the study.
Bittner pointed out that attendance, enrollment, and completion might be problematic with stroke patients, just as they have been with heart failure and post-myocardial infarction patients, among others.
The analysis included 19 studies ("ranging from single-group convenience samples to randomized control trials with control groups and assessor blinding") with 23 treatment groups across the studies, comprising 485 participants with mean ages ranging from 54 to 71 years.
Over about a 3 month period, participants went to two to three sessions each week. Walking, mixed mode aerobic exercise, and stationary cycling were common types of activity.
VO2 peak had a pooled difference in means of 2.08 mL/kg per minute (95% CI 1.18–2.98) and a summary effect size of 0.38 (95% CI 0.17–0.60).
When it came to the 6-minute walk test, there was a pooled difference in means of 53.3 m (95% CI 36.8–69.8) and a summary effect size of 0.41 (95% CI 0.25–0.58). Similar improvement data were shown for self-selected walking speed and maximum walking speed.
Inclusion criteria for the studies were:
  • An intervention dosage of 18 to 36 visits in total over 8 to 18 weeks
  • A cohort of adult survivors of stroke
  • A study design that consisted of pretesting and posttesting for an intervention for one group or more
  • An outcome measure that involved one or more measures of aerobic capacity
Studies were excluded if they involved aquatic-based or individual or nongroup activity, offered physical assistance to the participant other than equipment setup, or included other interventions or physical therapy beyond aerobic exercise or stretching, educational sessions, or resistance exercise.
Limitations included the variety of study designs, lack of follow-up information, and lack of control group comparisons. Regan and colleagues noted available studies mainly focused on survivors of stroke with mild mobility impairments, and narrow frequency and duration criteria hindered the ability to determine if less frequent or shorter duration interventions offered similar benefits.
"More studies with follow-up periods after primary group intervention and evaluation of cost and healthcare use could provide insight on the importance of continued services and their economic impact," the researchers concluded.
The study was funded by the Foundation for Physical Therapy, the American Heart Association Pre-Doctoral Fellowship, the Arnold School of Public Health, the National Institutes of Health, the National Institute of General Medical Sciences, the University of South Carolina, and the University of South Carolina Behavioral-Biomedical Interface Program.
Regan reported no disclosures.
Bittner disclosed relationships with Amgen, Sanofi, AstraZeneca, DalCor, The Medicines Company, and Esperion.

No comments:

Post a Comment